DOCSLIB.ORG

Dystrophin Gene Abnormalities in Two Patients with Idiopathic Dilated Cardiomyopathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dystrophin Gene Abnormalities in Two Patients with Idiopathic Dilated Cardiomyopathy 608 Heart 1997;78:608–612 CASE STUDY Heart: first published as 10.1136/hrt.78.6.608 on 1 December 1997. Downloaded from Dystrophin gene abnormalities in two patients with idiopathic dilated cardiomyopathy Francesco Muntoni, Andrea Di Lenarda, Maurizio Porcu, Gianfranco Sinagra, Anna Mateddu, Gianni Marrosu, Alessandra Ferlini, Milena Cau, Jelena Milasin, Maria Antonietta Melis, Maria Giovanna Marrosu, Carlo Cianchetti, Antonio Sanna, Arturo Falaschi, Fulvio Camerini, Mauro Giacca, Luisa Mestroni Abstract Cardiac involvement is an integral part of Neuromuscular Unit, Two new cases of dilated cardiomyopathy DMD and BMD.4–7 In rare instances, however, Department of Paediatrics and (DC) caused by dystrophinopathy are patients can suVer from dilated cardiomyo- Neonatal Medicine, reported. One patient, a 24 year old man, pathy (DC) as the only manifestation of a dys- Hammersmith had a family history of X linked DC, while trophinopathy. This has been now recognised Hospital, London, UK the other, a 52 year old man, had sporadic in families with typical X linked DC8–11 and in F Muntoni patients with sporadic disease.12–14 Unlike A Ferlini disease. Each had abnormal dystrophin immunostaining in muscle or cardiac patients with DMD or BMD, these patients did International Centre biopsy specimens, but neither had muscle not have symptoms of muscle weakness and the for Genetic weakness. Serum creatine kinase activity only sign of neuromuscular involvement was Engineering and was raised only in the patient with familial raised serum creatine kinase (CK) activity. Biotechnology e disease. Analysis of dystrophin gene mu- Several patients had mutations clustered in the Divisione di 91112 tations showed a deletion of exons 48–49 in 5' end of the gene ; a region not aVected by Cardiologia, Ospedale mutations usually found in DMD and BMD. e Università di Trieste, the patient with familial DC and of exons DC has also been reported in asymptomatic Trieste, Italy 49–51 in the other. Dystrophin transcrip- 15 A Di Lenarda female carriers of DMD and BMD. tion in cardiac tissue from the patient with http://heart.bmj.com/ G Sinagra sporadic disease showed abundant expres- Two cases of familial (X linked) and sporadic J Milasin sion, predominantly of the muscle iso- DC secondary to a dystrophinotrophy are A Falaschi reported here. F Camerini form. This study, together with previous M Giacca reports, suggests that some patients with L Mestroni DC have a dystrophinopathy that can be Patients diagnosed using a combination of bio- The two patients described in this study origi- Divisione di nate from Italy. Ethical approval was obtained Cardiologia, Ospedale chemical and genetic analyses. (Heart 1997;78:608–612) from the committees of the two hospitals Brotzu, Italy on September 29, 2021 by guest. Protected copyright. M Porcu involved in their assessment. Informed consent A Sanna Keywords: dilated cardiomyopathy; dystrophin; Becker was obtained from each patient. muscular dystrophy Istituto di PATIENT 1 Neuropsichiatria The first patient, a 24 year old man, was Infantile, Italy Duchenne’s (DMD) and Becker’s muscular admitted in August 1991 after the recent onset A Mateddu dystrophies (BMD) are allelic X linked neuro- G Marrosu of dyspnoea with mild physical activity. DC was M G Marrosu muscular disorders. They result from muta- diagnosed (left ventricular end diastolic diam- C Cianchetti tions in the dystrophin gene that, when severe eter 73 mm; left ventricular end diastolic as in DMD (nonsense or out of frame volume 107 ml/mq; left ventricular ejection Dipartimento di mutations), lead to lack of expression of the fraction 27%) after exclusion of active myocar- Biologia e Clinica sarcolemmal protein dystrophin.1 Up to one dell’Età Evolutiva, ditis by endomyocardial biopsy and coronary Cagliari, Italy third of all cases of DMD and BMD arise from artery disease by angiography. An electrocar- M Cau de novo mutations, so that a significant diogram showed Q waves in the inferior and M A Merlis proportion of aVected males have no family posterior leads and incomplete right bundle history of the condition.12The absence of dys- brunch block. Sustained ventricular arrhyth- Correspondence to: trophin in DMD causes severe and progressive Dr Muntoni, Department of mias were detected after 24 hour Holter moni- Paediatrics and Neonatal muscle weakness, loss of ambulation before the toring. Among the biochemical investigations, Medicine, Royal age of 13, and death in the late teens or early constantly raised serum CK activity (MM iso- Postgraduate Medical twenties.3 BMD is a milder form of muscular School, Hammersmith form, ranging between 540 and 867 U/l, Hospital, Du Cane Road, dystrophy in which individuals are ambulant normal < 200 U/l) was found. Neurological London W12 ONN, UK; after the age of 16. These individuals usually investigation failed to show any weakness or email: [email protected] have in frame deletions and residual expression muscle wasting or hypertrophy. The patient Accepted for publication of a partially functional dystrophin in the denied symptoms of neuromuscular involve- 22 July 1997 muscle.3 ment such as cramps or myalgias associated Dystrophin in dilated cardiomyopathy 609 venous pressure or peripheral oedema. His liver was enlarged and neurological examin- Heart: first published as 10.1136/hrt.78.6.608 on 1 December 1997. Downloaded from ation failed to show muscle atrophy or pseudo- hypertrophy. His muscle strength was normal, as was serum CK activity (84 U/l). Negative T waves in leads V5–V6 were seen on the electro- cardiogram. Echocardiography showed a di- lated left ventricle (left ventricular end diastolic diameter 70 mm, left ventricular ejection frac- tion 20%). The right ventricle and both atria were also dilated. Moderate mitral and tricus- pidal valve regurgitation was also found. Right heart catheterisation disclosed pulmonary hy- Figure 1 Pedigree of family with X linked cardiomyopathy. Open symbols, unaVected pertension, (pulmonary artery pressure 68/ individuals; closed circles, aVected individuals; barred symbols, deceased (number above is 30 mm Hg, mean 42 mm Hg), and a reduced age at death); dotted circles, obligate carriers; arrow, propositus. cardiac index (2.0 l/min/m2). Despite medical treatment with angiotensin converting enzyme with exercise. He improved following treat- inhibitors, digitalis, and diuretics the patient ment with digitalis, enalapril, and metoprolol deteriorated clinically and he underwent car- and remained in New York Heart Assocation diac transplantation nine months later. In the (NYHA) class I–II. During follow up the left early postoperative period he suVered from ventricular dimension slightly diminished (left multiorgan failure and died shortly after. ventricular end diastolic diameter 70 mm), although the systolic function remained signifi- Methods cantly depressed (left ventricular ejection frac- IMMUNOHISTOCHEMICAL STUDY OF SKELETAL tion 37%) with diVuse wall motion abnormali- AND CARDIAC MUSCLE ties, more evident in the inferoposterior region. A cardiac biopsy specimen obtained at Mild right ventricular dysfunction was ob- cardiac transplantation, and a needle biopsy served at radionuclide angiography (right ven- specimen of skeletal muscle taken from patient tricular ejection fraction 35%). At the last 1 were immediately frozen in liquid nitrogen follow up (1996) the patient was in NYHA cooled isopentane and stored at −70ºC or in class II with a peak consumption of oxygen of liquid nitrogen. The specimens were fully 14.4 ml/kg/min (anaerobic threshold 5.8 ml/ processed for histological, histochemical, and kg/min) and without evidence of electrical ven- immunohistochemical examination.16 In par- tricular instability with Holter monitoring or ticular, unfixed cryostat sections (6 µm) were during exercise. immunostained using a panel of six antidys- Analysis of the pedigree disclosed a strong trophin antibodies, including the monoclonal http://heart.bmj.com/ family history of DC suggestive of an X linked antibody DYS1808 (Ylem, Italy), as already inheritance (fig 1). Individuals II:3, III:6, and described.17 III:11 (fig 1) had been aVected by DC and died at the ages of 36, 42, and 38, respectively. DNA STUDIES Moreover, a maternal aunt (individual II:5, fig DNA was isolated from leucocytes by standard 1), an obligate carrier for the condition, also methods. Multiplex DNA amplification of dys- died of DC at the age of 57. Interestingly, indi- trophin exons was carried out according to vidual III:8 had DMD and died because of res- previously described techniques.18 19 piratory complications at the age of 22. All on September 29, 2021 by guest. Protected copyright. other aVected members did not have signs of REVERSE TRANSCRIPTION AND POLYMERASE skeletal muscle involvement, at least as far as CHAIN REACTION could be assessed from their medical records Total RNA20 was isolated from control frozen and questioning their relatives. A needle skeletal muscle and heart and from the left muscle biopsy specimen from the propositus ventricle of patient 2. cDNA synthesis was (individual III:4, fig 1) was obtained to investi- performed using random hexanucleotide prim- gate the possibility of an underlying dystrophi- ers, following the procedure already nopathy. described.21 22 Polymerase chain reaction was performed using forward primers designed to PATIENT 2 amplify the muscle, brain, and Purkinje cell The second patient, a 52 year old man, died isoforms and an exon 6 reverse primer as shortly after cardiac transplantation in 1994. already described.21 He was employed in the chemical industry and was physically active until the age of 50 when Results he presented with the first symptoms of cardiac IMMUNOHISTOCHEMICAL ANALYSIS failure. There was no family history of cardio- The skeletal muscle biopsy specimen from the vascular disease. The patient smoked 20 propositus showed mild dystrophic changes, cigarettes daily and admitted moderate alcohol characterised by an increase in internal nuclei intake until the age of 50, when he developed a (12%), mild variability of fibre size with hypo- gastric peptic ulcer that eventually required trophic and hypertrophic fibres, and rare fibre surgical excision.
Load more

Recommended publications
  • Genotype–Phenotype Correlations in Duchenne and Becker Muscular Dystrophy Patients from the Canadian Neuromuscular Disease Registry
    Journal of Personalized Medicine Article Genotype–Phenotype Correlations in Duchenne and Becker Muscular Dystrophy Patients from the Canadian Neuromuscular Disease Registry 1, 1, 1,2, Kenji Rowel Q. Lim y , Quynh Nguyen y and Toshifumi Yokota * 1 Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G2H7, Canada; [email protected] (K.R.Q.L.); [email protected] (Q.N.) 2 The Friends of Garrett Cumming Research & Muscular Dystrophy Canada, HM Toupin Neurological Science Research Chair, Edmonton, AB T6G2H7, Canada * Correspondence: [email protected]; Tel.: +1-780-492-1102 These authors contributed equally to this work. y Received: 29 October 2020; Accepted: 21 November 2020; Published: 23 November 2020 Abstract: Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disorder generally caused by out-of-frame mutations in the DMD gene. In contrast, in-frame mutations usually give rise to the milder Becker muscular dystrophy (BMD). However, this reading frame rule does not always hold true. Therefore, an understanding of the relationships between genotype and phenotype is important for informing diagnosis and disease management, as well as the development of genetic therapies. Here, we evaluated genotype–phenotype correlations in DMD and BMD patients enrolled in the Canadian Neuromuscular Disease Registry from 2012 to 2019. Data from 342 DMD and 60 BMD patients with genetic test results were analyzed. The majority of patients had deletions (71%), followed by small mutations (17%) and duplications (10%); 2% had negative results. Two deletion hotspots were identified, exons 3–20 and exons 45–55, harboring 86% of deletions. Exceptions to the reading frame rule were found in 13% of patients with deletions.
    [Show full text]
  • Muscular Dystrophies and the Heart: the Emerging Role of Cardiovascular Magnetic Resonance Imaging
    REVIEW Muscular dystrophies and the heart: The emerging role of cardiovascular magnetic resonance imaging Sophie Mavrogeni MD1, George Markousis-Mavrogenis MD1, Antigoni Papavasiliou MD2, Elias Gialafos MD3, Stylianos Gatzonis MD4, George Papadopoulos MD5, Genovefa Kolovou MD1 S Mavrogeni, G Markousis-Mavrogenis, A Papavasiliou, et al. hypertrophy and, potentially, evidence of myocardial necrosis, depend- Muscular dystrophies and the heart: The emerging role of ing on the type of MD. Echocardiography is a routine technique used to cardiovascular magnetic resonance imaging. Curr Res Cardiol assess left ventricular dysfunction, independent of age of onset or muta- 2015;2(2):53-62. tion. In some cases, it can also identify early, silent cardiac dysfunction. CMR is the best technique for accurate and reproducible quantification of ventricular volumes, mass and ejection fraction. CMR has docu- Muscular dystrophies (MD) constitute a group of inherited disorders, mented a pattern of epicardial fibrosis in both dystrophinopathy patients characterized by progressive skeletal muscle weakness and heart involve- and mutation carriers that can be observed even if overt muscular disease ment. Cardiac disease is common and not necessarily related to the is absent. Recently, CMR techniques, such as postcontrast myocardial T1 degree of skeletal myopathy; it may be the predominant manifestation mapping, have been used in Duchenne muscular dystrophy to detect dif- with or without any other evidence of muscular disease. Death is usually fuse myocardial fibrosis. A combined approach using clinical assessment due to ventricular dysfunction, heart block or malignant arrhythmias. and CMR evaluation may motivate early cardioprotective treatment in In addition to MD patients, female carriers may present with cardiac both patients and asymptomatic carriers, and prevent the development of involvement.
    [Show full text]
  • Current and Emerging Therapies in Becker Muscular Dystrophy (BMD)
    Acta Myologica • 2019; XXXVIII: p. 172-179 OPEN ACCESS © Gaetano Conte Academy - Mediterranean Society of Myology Current and emerging therapies in Becker muscular dystrophy (BMD) Corrado Angelini, Roberta Marozzo and Valentina Pegoraro Neuromuscular Center, IRCCS San Camillo Hospital, Venice, Italy Becker muscular dystrophy (BMD) has onset usually in child- tients with a deletion in the dystrophin gene that have nor- hood, frequently by 11 years. BMD can present in several ways mal muscle strength and endurance, but present high CK, such as waddling gait, exercise related cramps with or with- and so far their follow-up and treatment recommenda- out myoglobinuria. Rarely cardiomyopathy might be the pre- senting feature. The evolution is variable. BMD is caused by tions are still a matter of debate. Patients with early cardi- dystrophin deficiency due to inframe deletions, mutations or omyopathy are also a possible variant of BMD (4, 5) and duplications in dystrophin gene (Xp21.2) We review here the may be susceptible either to specific drug therapy and/or evolution and current therapy presenting a personal series of to cardiac transplantation (6-8). Here we cover emerging cases followed for over two decades, with multifactorial treat- therapies considering follow-up, and exemplifying some ment regimen. Early treatment includes steroid treatment that phenotypes and treatments by a few study cases. has been analized and personalized for each case. Early treat- ment of cardiomyopathy with ACE inhibitors is recommended and referral for cardiac transplantation is appropriate in severe cases. Management includes multidisciplinary care with physi- Pathophysiology and rationale of otherapy to reduce joint contractures and prolong walking.
    [Show full text]
  • 226Th ENMC International Workshop: Towards Validated and Qualified Biomarkers for Therapy Development for Duchenne Muscular Dyst
    Available online at www.sciencedirect.com ScienceDirect Neuromuscular Disorders 28 (2018) 77–86 www.elsevier.com/locate/nmd Workshop report 226th ENMC International Workshop: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20–22 January 2017, Heemskerk, The Netherlands Annemieke Aartsma-Rus a,*, Alessandra Ferlini b,c, Elizabeth M. McNally d, Pietro Spitali a, H. Lee Sweeney e, on behalf of the workshop participants a Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands b Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Italy c Dubowitz Neuromuscular Unit, UCL, London d Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL USA e Myology Institute, Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA Received 25 July 2017 Keywords: Duchenne muscular dystrophy; Biomarker; Dystrophin; MRI; Biobank 1. Introduction therapeutic biomarkers are designed to predict or measure response to treatment [1]. Therapeutic biomarkers can indicate Twenty-three participants from 6 countries (England; whether a therapy is having an effect. This type of biomarker is Germany; Italy; Sweden, The Netherlands; USA) attended the called a pharmacodynamics biomarker and can be used to e.g. 226th ENMC workshop on Duchenne biomarkers “Towards show that a missing protein is restored after a therapy. Safety validated and qualified biomarkers for therapy development for biomarkers assess likelihood, presence, or extent of toxicity as Duchenne Muscular Dystrophy.” The meeting was a follow-up an adverse effect, e.g. through monitoring blood markers of the 204th ENMC workshop on Duchenne muscular indicative of liver or kidney damage.
    [Show full text]
  • 107Th ENMC International Workshop: the Management of Cardiac Involvement in Muscular Dystrophy and Myotonic Dystrophy
    Neuromuscular Disorders 13 (2003) 166–172 www.elsevier.com/locate/nmd Workshop report 107th ENMC International Workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th–9th June 2002, Naarden, the Netherlands K. Bushby*, F. Muntoni, J.P. Bourke Department of Neuromuscular Genetics, Institute of Human Genetics, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK Received 1 August 2002; accepted 16 August 2002 1. Introduction symptomatic presentation [13,14]. Although evidence in these rare conditions of the effect of treatment is lacking Sixteen participants from Austria, France, Germany, [15], extrapolation from other conditions causing heart fail- Italy, the Netherlands and the UK met to discuss the cardiac ure with dilated cardiomyopathy means that there is a strong implications of the diagnosis of muscular dystrophy and case for the use of ACE inhibitors and potentially also beta myotonic dystrophy. The group included both myologists blockers, certainly in the presence of detectable abnormal- and cardiologists from nine different European centers. The ities and possibly preventatively [16–25]. aims of the workshop were to agree and report minimum The recommendations of the group are as follows. recommendations for the investigation and treatment of cardiac involvement in muscular and myotonic dystrophies, 2.1. DMD and define areas where further research is needed. During the workshop, all participants contributed to a review and † Patients should have a cardiac investigation (echo and assessment of the published evidence in each area and electrocardiogram (ECG)) at diagnosis. current practice amongst the group. Consensus statements † DMD patients should have cardiac investigations before for the management of dystrophinopathy, myotonic dystro- any surgery, every 2 years to age 10 and annually after phy, limb-girdle muscular dystrophy, Emery Dreifuss age 10.
    [Show full text]
  • The Limb-Girdle Muscular Dystrophies and the Dystrophinopathies Review Article
    Review Article 04/25/2018 on mAXWo3ZnzwrcFjDdvMDuzVysskaX4mZb8eYMgWVSPGPJOZ9l+mqFwgfuplwVY+jMyQlPQmIFeWtrhxj7jpeO+505hdQh14PDzV4LwkY42MCrzQCKIlw0d1O4YvrWMUvvHuYO4RRbviuuWR5DqyTbTk/icsrdbT0HfRYk7+ZAGvALtKGnuDXDohHaxFFu/7KNo26hIfzU/+BCy16w7w1bDw== by https://journals.lww.com/continuum from Downloaded Downloaded from Address correspondence to https://journals.lww.com/continuum Dr Stanley Jones P. Iyadurai, Ohio State University, Wexner The Limb-Girdle Medical Center, Department of Neurology, 395 W 12th Ave, Columbus, OH 43210, Muscular Dystrophies and [email protected]. Relationship Disclosure: by mAXWo3ZnzwrcFjDdvMDuzVysskaX4mZb8eYMgWVSPGPJOZ9l+mqFwgfuplwVY+jMyQlPQmIFeWtrhxj7jpeO+505hdQh14PDzV4LwkY42MCrzQCKIlw0d1O4YvrWMUvvHuYO4RRbviuuWR5DqyTbTk/icsrdbT0HfRYk7+ZAGvALtKGnuDXDohHaxFFu/7KNo26hIfzU/+BCy16w7w1bDw== Dr Iyadurai has received the Dystrophinopathies personal compensation for serving on the advisory boards of Allergan; Alnylam Stanley Jones P. Iyadurai, MSc, PhD, MD; John T. Kissel, MD, FAAN Pharmaceuticals, Inc; CSL Behring; and Pfizer, Inc. Dr Kissel has received personal ABSTRACT compensation for serving on a consulting board of AveXis, Purpose of Review: The classic approach to identifying and accurately diagnosing limb- Inc; as journal editor of Muscle girdle muscular dystrophies (LGMDs) relied heavily on phenotypic characterization and & Nerve; and as a consultant ancillary studies including muscle biopsy. Because of rapid advances in genetic sequencing for Novartis AG. Dr Kissel has received research/grant methodologies,
    [Show full text]
  • Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy
    International Journal of Molecular Sciences Review Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy: Exploration of Steroid-Sparing Agents Sandrine Herbelet 1,* , Arthur Rodenbach 1 , Boel De Paepe 1,2 and Jan L. De Bleecker 1,2 1 Department of Head and Skin, Division of Neurology, Ghent University and Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium; [email protected] (A.R.); [email protected] (B.D.P.); [email protected] (J.L.D.B.) 2 Neuromuscular Reference Center, Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium * Correspondence: [email protected]; Tel.: +32-9332-89-84; Fax: +32-9332-49-71 Received: 26 May 2020; Accepted: 27 June 2020; Published: 28 June 2020 Abstract: In Duchenne muscular dystrophy (DMD), the activation of proinflammatory and metabolic cellular pathways in skeletal muscle cells is an inherent characteristic. Synthetic glucocorticoid intake counteracts the majority of these mechanisms. However, glucocorticoids induce burdensome secondary effects, including hypertension, arrhythmias, hyperglycemia, osteoporosis, weight gain, growth delay, skin thinning, cushingoid appearance, and tissue-specific glucocorticoid resistance. Hence, lowering the glucocorticoid dosage could be beneficial for DMD patients. A more profound insight into the major cellular pathways that are stabilized after synthetic glucocorticoid administration in DMD is needed when searching for the molecules able to achieve similar pathway stabilization. This review provides a concise overview of the major anti-inflammatory pathways, as well as the metabolic effects of glucocorticoids in the skeletal muscle affected in DMD. The known drugs able to stabilize these pathways, and which could potentially be combined with glucocorticoid therapy as steroid-sparing agents, are described.
    [Show full text]
  • Protein Aggregate Myopathies
    Review Article Protein aggregate myopathies M. C. Sharma, H. H. Goebel1 All India Institute of Medical Sciences, New Delhi, India and 1Department of Neuropathology, Johannes Gutenberg University Medical Center, Mainz, Germany Protein aggregate myopathies (PAM) are an emerging group Aggegation of proteins within muscle cells may be of lyso- of muscle diseases characterized by structural abnormali- somal or nonlysosomal nature. The former occurs, for instance, ties. Protein aggregate myopathies are marked by the ag- in the neuronal ceroid-lipofuscinoses (NCL) as components gregation of intrinsic proteins within muscle fibers and fall of lipopigments, their accretion being a morphological hall- into four major groups or conditions: (1) desmin-related mark in the NCL.[1] This lysosomal accumulation of myopathies (DRM) that include desminopathies, a-B lipopigments renders the NCL a member of the lysosomal dis- crystallinopathies, selenoproteinopathies caused by muta- orders among which type-II glycogenosis, Niemann-Pick dis- tions in the, a-B crystallin and selenoprotein N1 genes, (2) ease, mucolipidosis IV and others may affect the skeletal hereditary inclusion body myopathies, several of which have muscle. been linked to different chromosomal gene loci, but with as Nonlysosomal accumulation of proteins within muscle fibers yet unidentified protein product, (3) actinopathies marked is a hallmark of a recently emerging subgroup of myopathies, by mutations in the sarcomeric ACTA1 gene, and (4) called protein aggregate myopathies (PAM). The cause
    [Show full text]
  • The Histopathological Features of Muscular Dystrophies
    SMGr up The Histopathological Features of Muscular Dystrophies Gulden Diniz* Pathologist, Microbiologist and Basic Oncologist, Neuromuscular Diseases’ Centre of Izmir Tepecik Education and Research Hospital, Turkey *Corresponding author: Gulden Diniz, Pathologist, Microbiologist and Basic Oncologist, Neuromuscular Diseases’ Centre of Izmir Tepecik Education and Research Hospital, Turkey. Email: [email protected] Published Date: September 23, 2016 ABSTRACT Muscular dystrophies are degenerative muscle diseases due to mutations in proteins ranging in function such as sarcolemmal structure, nuclear envelope structure, or post-translational suggesting that biological differences exist between individual muscles that predispose them to glycosylation. Each of them affects a specific group of skeletal muscles within the human body, specificClinical pathological manifestation etiologies. of different muscular dystrophies is now well known and documented. Dystrophinopathies are X-linked recessive diseases and the most common form of muscular dystrophies with a relatively poor outcome. Other recognized varieties of muscular dystrophies limb girdle muscular dystrophy is an umbrella name for a group of diseases which exhibits are classified into different groups according to their clinical or genetic similarities. For example, congenital muscular dystrophies is presentation prior to 1 year of age. proximal weakness of the shoulder and pelvic girdles. Similarly, the defining characteristic of Muscular Dystrophy | www.smgebooks.com 1 Copyright Diniz
    [Show full text]
  • Duchenne Muscular Dystrophy: from Diagnosis to Therapy
    Molecules 2015, 20, 18168-18184; doi:10.3390/molecules201018168 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Duchenne Muscular Dystrophy: From Diagnosis to Therapy Maria Sofia Falzarano 1,*, Chiara Scotton 1, Chiara Passarelli 2 and Alessandra Ferlini 1,* 1 Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, 44121 Italy; E-Mail: [email protected] 2 Bambino Gesù Hospital, Rome, 00146, Italy; E-Mail: [email protected] * Authors to whom correspondence should be addressed; E-Mails: [email protected] (M.S.F.); [email protected] (A.F.); Tel.: +39-0532-974404 (A.F.); Fax: +39-0532-974406 (A.F.). Academic Editor: Leonidas A. Phylactou Received: 20 July 2015 / Accepted: 28 September 2015 / Published: 7 October 2015 Abstract: Duchenne muscular dystrophy (DMD) is an X-linked inherited neuromuscular disorder due to mutations in the dystrophin gene. It is characterized by progressive muscle weakness and wasting due to the absence of dystrophin protein that causes degeneration of skeletal and cardiac muscle. The molecular diagnostic of DMD involves a deletions/duplications analysis performed by quantitative technique such as microarray-based comparative genomic hybridization (array-CGH), Multiple Ligation Probe Assay MLPA. Since traditional methods for detection of point mutations and other sequence variants require high cost and are time consuming, especially for a large gene like dystrophin, the use of next-generation sequencing (NGS) has become a useful tool available for clinical diagnosis. The dystrophin gene is large and finely regulated in terms of tissue expression, and RNA processing and editing includes a variety of fine tuned processes.
    [Show full text]
  • Pokroky V Léčbě Hereditárních Svalových Chorob
    Přehledové články 191 Pokroky v léčbě hereditárních svalových chorob MUDr. Stanislav Voháňka, CSc., MBA Neurologická klinika LF MU a FN Brno Pokroky v léčbě svalových dystrofií lze rozdělit na dvě základní skupiny. Aktuální symptomatickou péči a pokroky v genové a patoge- neticky orientované terapii. Symptomatická péče, přestože neléčí podstatu nemoci, je velmi významná a zvyšuje kvalitu a délku života nemocných. Jde o prodlužování schopnosti chůze pomocí ortéz, podporu ventilace a kardiologickou péči. Srdečnímu postižení je třeba věnovat odpovídající pozornost, u některých svalových chorob jde o limitující postižení (Emeryho Dreifussova svalová dystrofie, dys- trofinopatie). Za symptomatickou farmakoterapii lze také považovat podávání kortikosteroidů u chlapců s dystrofinopatií. Etiopatogeneticky orientovaná léčba se u pacientů s dystrofinopatií dělí na genovou terapii, buněčnou terapii a farmakoterapii. Experi- menty v oblasti genové terapie se soustředí na přenos mikrodystrofinu do genomu pomocí virového nosiče. Hlavní překážkou je zatím autoimunitní reakce organizmu. Se stejnými potížemi se potýká i buněčná terapie s lokální aplikací myoblastů, mezangioblastů a CD133+ buněk. Farmakoterapie je zaměřena na léky podporující upregulaci exprese utrofinu, který může částečně nahradit funkci dystrofinu: bylo zahájeno testování látky BMN195 na zdravých dobrovolnících. Dalším perspektivním směrem jsou inhibitory myostatinu, tedy látky zasahující do funkce genu GDF-8, jde o monoklonální protilátky ACE-031 a MYO-029 a látku ACVR2B. Další velkou skupinou jsou tzv. mutačně specifické přístupy. Látka PTC 124 umožňuje u nemocných s dystrofinopatií Duchennerova typu překlenutí bodové mutace se stop kodonem a tedy tvorbu sice mutovaného, ale alespoň částečně funkčního dystrofinu. Nadějné experimentální výsledky se bo- hužel neukázaly v klinické praxi účinné a klinická studie ve fázi IIb byla zastavena (Ataluren®).
    [Show full text]
  • Approach to Patients with Neuromuscular Disorders
    Approach to Patients With Neuromuscular Disorders Anthony A. Amato, MD Chief, Neuromuscular Division and Director, Clinical Neurophysiology Laboratory Brigham and Women’s Hospital Associate Professor of Neurology Harvard Medical School Boston, Massachusetts INTRODUCTION a true sensory level is not evident in GBS but should be present in transverse myelitis and other structural abnormalities involving the The approach to patients with neuromuscular disorders is chal- spinal cord. lenging. As in other neurological diseases the key to arriving at the correct diagnosis is careful localization of the lesion. Weakness can The presence of motor and sensory symptoms and signs are helpful be the result of central lesions (brain or spinal cord processes—e.g., in distinguishing peripheral neuropathies from anterior horn cell brainstem infarct, central pontine myelinolysis, transverse myelopa- disorders, myopathies, and neuromuscular junction disorders. thy), anterior horn cell disease (e.g., amyotrophic lateral sclerosis However, some types of peripheral neuropathy are predominantly [ALS], poliomyelitis), peripheral neuropathy (e.g., Guillain-Barré or purely motor and thus can be difficult to distinguish these other syndrome [GBS]), neuromuscular junction defects (botulism, disease processes. Most neuropathies are associated with distal Lambert-Eaton myasthenic syndrome [LEMS], myasthenia gravis greater than proximal weakness. However, significant proximal [MG]), or myopathic disorders. The most important aspect of as- weakness can be seen in certain peripheral neuropathies (e.g., GBS, sessing individuals with neuromuscular disorders is taking a thor- chronic inflammatory demyelinating polyneuropathy [CIDP]). ough history of the patient’s symptoms, disease progression, and Further, although usually associated with proximal weakness, past medical and family history as well as performing a detailed certain myopathies and rarely even neuromuscular junction disor- neurologic examination.
    [Show full text]